Although detection of TP53mut using next-generation sequencing (NGS) is still not part of many studies (Rees et al. 2024; Petrackova et al. 2020), new International Myeloma Society/International Myeloma Working Group (IMS/IMWG) Consensus 2025 recommends investigation of TP53 mutations as part of routine practice (Avet-Loiseau et al. 2025). This evidence concerns the gene TP53 and plasma cell myeloma.